D-Pharm

Kiryat Weizmann Science Park, Bldg. 7, P.O. Box 2313, Rehovot 76123, Israel 47 Hulfish Street, Suite 310 Princeton, NJ 08642

D-Pharm is a specialty pharmaceutical company that designs and develops innovative drugs for the treatment of the most devastating brain disorders. The Company has developed two unique platform technologies that generate lipid–like medicines which utilise lipid specific mechanisms and lipid-related pathways in living cells. Additional therapeutic applications for DP-b99 include: Traumatic Brain Injury (TBI) and diminishing the risk of brain damage associated with Coronary Artery Bypass Graft surgery (CABG); and for DP-VPA include Bipolar disorder and prophylaxis of Migraine. In addition, the Company possesses a pipeline of pre-clinical candidates for treatment of neuro-degenerative diseases, other CNS disorders and cancer. The most advanced of these candidates is DP-460 for the treatment of Alzheimer’s disease.

EPIX Pharmaceuticals

4 Maguire Rd, Lexington, MA 02421 S.A.P. Building, 3 Hayetzira St, Ramat-Gan 52521 Israel

EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products through the use of proprietary technology to better diagnose, treat and manage patients. The company has five internally-discovered therapeutic and imaging drug candidates currently in clinical trials targeting conditions such as depression, Alzheimer's disease, cardiovascular disease and obesity.

Medgenics

8000 Towers Crescent Dr., Suite 1300, Vienna, VA 22182 12 Hanapach St., P.O. Box 6314, Karmiel, 21653 Israel

Medgenics’ breakthrough technology promises a safe, single treatment that replaces months of injections, and their undesirable side effects. Producing and delivering therapeutic proteins right under the patient’s skin, this patented platform technology offers a novel and superior form of protein therapy. Long-acting, low-cost and efficient, Medgenics technology offers benefits to patients, physicians and payers alike. The company has demonstrated proof of principle in clinical trials delivering erythropoietin (EPO) to anemic patients.

OMRIX Biopharmaceuticals, Inc.
(OMRI) 18.13

630 5th Avenue, 22nd Floor, New York, NY 10111 Ch de Waterloo 200, 1640 Rhode St Genèse, Brussels, Belgium MDA Blood Center, Tel Hashomer Hospital, 52621 Tel Aviv, Israel

Our biosurgical product line includes products and product candidates that are used for the control of bleeding, or hemostasis, and other surgical applications. We compete in the active biosurgical hemostats market, which we believe is the fastest growing segment of the surgical sealant market. We are currently partnered with Ethicon Inc., a Johnson & Johnson Company, in the development of unique biosurgical devices which will meet critical unmet medical needs. Our passive immunotherapy product line includes antibody-rich products and product candidates for the treatment of immune deficiencies and infectious diseases and for potential biodefense applications. We supply vaccinia immunoglobulin, or VIG, to several governments as a means to treat smallpox vaccine-related complications in the event of a smallpox terrorist attack . We currently market in Israel intravenous immunoglobulin, or IVIG, an antibody-based product used to treat primary immune deficiencies, as well as enriched hepatitis B immune globulin (HBIG), and we are broadening our passive immunotherapy platform by improving our current products and developing new product candidates.

Pharma Focus Israel

56 Haatzamaut St, POB 1142, Yehud 56304 Israel

PFC Pharma Focus is a premium International Research Management Organization providing product development services in the life science and health care industries. Founded in 1992 by prominent experts in all realms of clinical services, the mission of PFC Pharma Focus is to bring a new look to the drug development experience by addressing the limitations of conventional study methods. With 15 years of extensive experience and more than 80% repeat business, we provide our clients with a superior drug development process through excellent project management, exceptional service, proactive solutions and high standards, always with the patient’s well-being in mind. Moreover, we are an industry leader in Investigator Initiated Trials (IITs), thus reducing structures and simplifying procedures. The personal experience of the PFC team runs through small start-up ventures, biotech and medical device companies to large pharmaceutical companies.

Proneuron Biotechnologies

2029 Century Park East, 6th Floor, Los Angeles, CA 90067 Weizmann Science Park, Building 14, P.O.B. 277 Ness-Ziona, 74101, Israel

Proneuron Biotechnologies is a biopharmaceutical company developing therapies for neurological disorders, including spinal cord injuries (SCI), brain trauma, and neurodegenerative diseases such as ALS, Huntington’s and Alzheimer’s diseases.

Rosetta Genomics
(ROSG) 1.13

10 Plaut St., Rehovot, Israel, 76706 675 U.S Highway one, Suite: B119, North Brunswick, NJ 08902

Rosetta Genomics is the first commercial entity to focus on the emerging field of microRNA. The company is a leader in medical research and product development based on microRNA. Using our own proprietary bioinformatic technologies, researchers at Rosetta Genomics have identified the majority of human microRNA of which we are aware. From this unparalleled intellectual property platform, Rosetta is actively advancing multiple internal programs in microRNA diagnostic and therapeutic product development. We are also establishing licensing agreements and collaborative relationships with leading companies and research institutions working to develop microRNA-based products.

Teva Pharmaceutical Industries Ltd.
(TEVA) 54.31

5 Basel St. Petach Tikva 49131, Israel

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products.

XTL Biopharmaceuticals
(XTLBY.PK) 0.11

PO Box 370, Rehovot 76100 ISRAEL

XTL Biopharmaceuticals is engaged in the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet medical needs, in particular the treatment of neuropathic pain and hepatitis C. We are developing Bicifadine for the treatment of neuropathic pain - a chronic condition resulting from damage to peripheral nerves. Bicifadine is a serotonin and norepinephrine reuptake inhibitor, or SNRI. Compared to the currently approved SNRI's, Bicifadine has a unique ratio of serotonin versus norepinephrine reuptake inhibition, which is weighted toward norepinephrine reuptake inhibition, providing a strong scientific rationale for using Bicifadine for the treatment neuropathic pain indications. We are developing DOS a pre-clinical program focused on the development of novel hepatitis C small molecule inhibitors. Compounds developed to date inhibit HCV replication in a pre-clinical cell-based assay with potencies comparable or superior to clinical stage drugs.